Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Alphavirus-based therapeutic immunization against cervical neoplasia: unraveling immunological mechanisms

02 November 2011

PhD ceremony: Mr. M. Walczak, 14.30 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Dissertation: Alphavirus-based therapeutic immunization against cervical neoplasia: unraveling immunological mechanisms

Promotor(s): prof. C.A.H.H. Daemen, prof. H.W. Nijman, prof. J.C. Wilschut

Faculty: Medical Sciences

Cervical cancer is caused by persistent infection with high-risk human papillomavirus (HPV). Prophylactic HPV-vaccination can prevent cervical cancer. Since available prophylactic HPV-vaccines cannot clear existing HPV-infections and commonly used methods to treat cervical cancer have reached the ceiling of their efficacy and may induce severe side effects, it is of great interest to develop novel therapeutic strategies to treat cervical cancer patients. One of these strategies may be immunotherapy as it is known that cellular immunity plays an important role in clearing HPV infection. Recombinant Semliki Forest virus replicon particles encoding a fusion protein of E6 and E7 from HPV type 16 (SFVeE6,7) represent a promising potential candidate for the therapeutic immunization against HPV-induced cervical cancer. In this thesis, tumor-specific immune responses induced by rSFV replicon particles were investigated and selected immunological mechanisms that influence these responses were elucidated. These immune responses were not (or only marginally) hampered by vector-specific immunity and regulatory T cells and could not be further improved using heterologous prime-boost immunization protocols. On the other hand, local tumor irradiation stimulated specific T cell trafficking (induced by rSFV immunization) into the tumor. Taken together, these pre-clinical studies indicate that rSFV replicon particles induce potent T cell immunity. Therefore therapeutic immunization based on the use of rSFV appears to be a promising and feasible approach to treat HPV-induced neoplasia. Clinical trials are required to prove the efficacy of rSFV in humans.

Last modified:15 September 2017 3.41 p.m.

More news

  • 23 April 2019

    From paperclip to patent

    How is it possible that an albatross doesn’t crash and die when it lands? And how come its large wings don’t break due to air resistance? That is what you would expect, according to the laws of aerodynamics. However, Professor Eize Stamhuis has discovered...

  • 16 April 2019

    A thorough characterization of structural variants in human genomes

    Human genomes vary quite a bit from individual to individual. These differences include single nucleotide changes, or “spelling mistakes” in the DNA sequence, but even more variation comes from structural variants, which include additions, deletions...

  • 02 April 2019

    ‘Sense of loss drives voting behaviour’

    ‘Everybody here loves that academia has returned to Friesland. We teach, carry out research and think along about solutions to problems that are relevant for Friesland,’ says Caspar van den Berg, Professor of Global and Local Governance at the UG Campus...